Efficacy and safety of tildrakizumab 100 mg for plaque psoriasis in patients randomized to treatment continuation vs treatment withdrawal with retreatment upon relapse in reSURFACE...

por Cantrell, W., Lee, P., Mendelsohn, A.M., Rozzo, S.J., Liao, W.
Publicado 2021

Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis: Letter to the Editor

por Gooderham, M., Elewski, B.E., Pariser, D.M., Sofen, H., Mendelsohn, A.M., Rozzo, S.J., Li, Q.
Publicado 2019

Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study

por Menter, M.A., Murakawa, G.J., Glover, H., Mendelsohn, A.M., Parno, J., Rozzo, S.J., Davidson, D., Gupta, A.K.
Publicado 2020

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2

por Fernandez, A.P., Dauden, E., Gerdes, S., Lebwohl, M.G., Menter, M.A., Leonardi, C.L., Gooderham, M., Gebauer, K., Tada, Y., Lacour, J.P., Bianchi, L., Egeberg, A., Pau‐Charles, I., Mendelsohn, A.M., Rozzo, S.J., Mehta, N.N.
Publicado 2022